Bone marrow transplant for multiple myeloma

Research output: Contribution to journalReview article

Abstract

Marrow transplantation for multiple myeloma is now a well-established therapeutic intervention. Allogeneic transplant has the advantage that it is potentially curative by virtue of graft versus myeloma effect. Unfortunately, the up-front mortality is approximately 40% in the first year. Autologous transplantation can be accomplished with a much lower risk of approximately 2-4%. Unfortunately, autologous transplantation is not curative for this disease and the median prolongation of survival is approximately 15 months. The ultimate role of transplantation in the overall management of younger patients with multiple myeloma remains a subject for future research.

Original languageEnglish (US)
Pages (from-to)297-302
Number of pages6
JournalCancer Research Therapy and Control
Volume9
Issue number3-4
StatePublished - Sep 29 1999

Fingerprint

Autologous Transplantation
Multiple Myeloma
Transplantation
Bone Marrow
Transplants
Survival
Mortality
Therapeutics

Keywords

  • Bone marrow transplantation
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bone marrow transplant for multiple myeloma. / Gertz, Morie.

In: Cancer Research Therapy and Control, Vol. 9, No. 3-4, 29.09.1999, p. 297-302.

Research output: Contribution to journalReview article

@article{3c6ebd82456c43dfa7602e334abdf7ee,
title = "Bone marrow transplant for multiple myeloma",
abstract = "Marrow transplantation for multiple myeloma is now a well-established therapeutic intervention. Allogeneic transplant has the advantage that it is potentially curative by virtue of graft versus myeloma effect. Unfortunately, the up-front mortality is approximately 40{\%} in the first year. Autologous transplantation can be accomplished with a much lower risk of approximately 2-4{\%}. Unfortunately, autologous transplantation is not curative for this disease and the median prolongation of survival is approximately 15 months. The ultimate role of transplantation in the overall management of younger patients with multiple myeloma remains a subject for future research.",
keywords = "Bone marrow transplantation, Multiple myeloma",
author = "Morie Gertz",
year = "1999",
month = "9",
day = "29",
language = "English (US)",
volume = "9",
pages = "297--302",
journal = "Cancer Research, Therapy and Control",
issn = "1064-0525",
publisher = "Harwood Academic Publishers",
number = "3-4",

}

TY - JOUR

T1 - Bone marrow transplant for multiple myeloma

AU - Gertz, Morie

PY - 1999/9/29

Y1 - 1999/9/29

N2 - Marrow transplantation for multiple myeloma is now a well-established therapeutic intervention. Allogeneic transplant has the advantage that it is potentially curative by virtue of graft versus myeloma effect. Unfortunately, the up-front mortality is approximately 40% in the first year. Autologous transplantation can be accomplished with a much lower risk of approximately 2-4%. Unfortunately, autologous transplantation is not curative for this disease and the median prolongation of survival is approximately 15 months. The ultimate role of transplantation in the overall management of younger patients with multiple myeloma remains a subject for future research.

AB - Marrow transplantation for multiple myeloma is now a well-established therapeutic intervention. Allogeneic transplant has the advantage that it is potentially curative by virtue of graft versus myeloma effect. Unfortunately, the up-front mortality is approximately 40% in the first year. Autologous transplantation can be accomplished with a much lower risk of approximately 2-4%. Unfortunately, autologous transplantation is not curative for this disease and the median prolongation of survival is approximately 15 months. The ultimate role of transplantation in the overall management of younger patients with multiple myeloma remains a subject for future research.

KW - Bone marrow transplantation

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=0032845801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032845801&partnerID=8YFLogxK

M3 - Review article

VL - 9

SP - 297

EP - 302

JO - Cancer Research, Therapy and Control

JF - Cancer Research, Therapy and Control

SN - 1064-0525

IS - 3-4

ER -